Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX22 in First-Line HER2+ Advanced Gastric Cancer
NCT04908813Phase 2Active, not recruiting
- Sponsor
- Henlius
- Start
- Sep 2021
- Primary completion
- Dec 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of hlx22 in gastric cancer (GC) (3 arms), sponsored by Henlius. Primary endpoints: Progression Free Survival up to 5 years and Objective Response Rate up to 5 years. Started Sep 2021; status: active, not recruiting.
02
Drugs
hlx22
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04908813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908813.